

## JHEP Reports

### CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

--

#### 1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.

#### 1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method

#### 1.3 Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall n number

#### 1.4 Sequence based reagents

Name	Sequence	Supplier
HO-1 Forward	5'-CCAGGCAGAGAATGCTGAGT-3'	Sigma-Aldrich
HO-1 Reverse	5'-GTAGACAGGGGCGAAGACTG-3'	Sigma-Aldrich
Catalase Forward	5'- ACCAGGGCATCAAACCTTT-3'	Sigma-Aldrich
Catalase Reverse	5'-CCGGATGCCATAGTCAGGAT-3'	Sigma-Aldrich
GCLM Forward	5'-GAAGAAGATATTTTTCTGTCATTGAT-3'	Sigma-Aldrich
GCLM Reverse	5'-CCATTCATGTATTGAAGAGTGAATTT-3'	Sigma-Aldrich
NQO1 Forward	5' -CTGATCGTACTGGCTCACTC-3'	Sigma-Aldrich
NQO1 Reverse	5'-AACAGACTCGGCAGGATAC-3'	Sigma-Aldrich
GPx Forward	5'-ACAACCACCCGGGACTTCA-3'	Sigma-Aldrich
GPx Reverse	5'-CCAAATTGGTTGCAAGGGAA-3'	Sigma-Aldrich
GCLC Forward	5'-ATTCCTGACATTCAAGCGCAC-3'	Sigma-Aldrich
GCLC Reverse	5'-TTCCTCTACTTTTACAATGACCGA-3'	Sigma-Aldrich
mnSOD Forward	5'-GGGTTGGCTTGGTTTCAATA-3'	Sigma-Aldrich
mnSOD Reverse	5'-CTGATTTGGACAAGCAGCAA-3'	Sigma-Aldrich
GAPDH Forward	5'-AGGTGAAGGTCGGAGTCA-3'	Sigma-Aldrich
GAPDH Reverse	5'-GGTCATTGATGGCAACAA-3'	Sigma-Aldrich

## 1.5 Biological samples

Description	Source	Identifier

## 1.6 Deposited data

Name of repository	Identifier	Link

## 1.7 Software

Software name	Manufacturer	Version
SPSS	IBM, Armonk, NY, USA	25.0
Excel Eiyō-Kun	Kenpakusya, Tokyo, Japan	4.0

## 1.8 Other (e.g. drugs, proteins, vectors etc.)


## 1.9 Please provide the details of the corresponding methods author for the manuscript:

Sechang Oh, Ph.D. Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan Phone: (+81) 29 853 3291; Fax: (+81) 29 853 3291 E-mail: ohsechang@md.tsukuba.ac.jp
--

## 2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

N/A
-----